GlaxoSmithKline (GSK) and Genmab A/S announced today the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for Arzerra(TM)(ofatumumab) for the treatment of chronic lymphocytic leukaemia (CLL).
The details can be read here.
No comments:
Post a Comment